Quality Control Scientist

Oncoinvent ASA is looking for a Scientist in the Quality Control department for a 12-month temporary position with the possibility of moving this to a permanent position. The position will be based at the company manufacturing facility in Oslo. The position is an exciting opportunity to work in an innovative and dynamic start-up company and participate in the production of novel pharmaceuticals.

What we are looking for is an individual enjoying working hands-on in the lab.

The successful candidate will, together with the Quality Control team, be responsible for quality control of raw materials, drug substance (Ra-224) and drug product (Radspherin®).

This position requires work with radioactive materials. A successful candidate is therefore expected to comply with radiation protection
and other health and safety procedures during laboratory- and production scale experiments, and GMP production activities.

Key responsibilities

  • Conduct chemical and physical release testing of raw materials, intermediates and
    finished product. Being hands-on on various types of tasks as required.
  • Develop analytical methods for testing raw materials, intermediates and finished product.
  • Participate in the validation of these test methods.
  • Investigate deviations and closing of the records in a timely fashion.
  • Resolve, in collaboration with the QC, QA and production team, out-of-specification
    or unexpected results and analytical- and product problems.
  • Maintain and troubleshoot analytical instrumentation as needed. Performing audits
    on equipment periodically to verify proper calibration and use.
  • Record and report result of analysis in accordance with prescribed lab procedures
    and systems.
  • Writing of SOPs and other instructional documents.
  • Procurement and qualification of analytical instruments.
  • Perform environmental monitoring.

Qualifications and experience

The holder of the QC Scientist position should have the following documented qualifications and experience:

  • Bachelor or master level within analytical chemistry or
    equivalent. Candidates with previous relevant experience are desirable, but
    recent graduates are also welcome to apply.
  • Experience with method development and method validation.
  • Experience with radiation protection and with a radiochemistry
    background is an advantage.
  • Knowledge of Good Manufacturing Practice (GMP).
  • Good language skills, written and spoken, in both Norwegian and English.

 

To be successful in the role, it is also important to have the following personal qualities:

  • Ability to work in a structured and independent manner
  • Conscious of responsibility
  • Good ability to implement and adapt
  •  Good communication skills and good at interacting with others
  • Solution-oriented
  • Ownership of own and others’ deliveries towards common goals
  •  

Location and working hours

The holder of this position will be based at Oncoinvent ASA, Gullhaugveien 7, 0484 Oslo. The position will report to the Head of Quality
Control.

The main part of the work will take place during normal working hours, but evening work and work on national holidays might occasionally be necessary for quality control of intermediate and final products.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product
candidate, Radspherin, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin in a clinical development program in two indications. In addition to the finalized phase 1/2a trial in colorectal cancer, one Phase 1 trial and one randomized Phase 2 trial, both in ovarian cancer are ongoing in the US, UK and Europe. Preliminary
clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo (ONCIN:OL).

 

Application deadline: We are reviewing candidates on a rolling basis.

Please submit your application with a motivational letter stating “why Oncoinvent” and what you can contribute to the position as well as an updated CV. Application without this will not be reviewed further.

 Contact:

Bjørn Fuglaas, 90775752

 

CEO Life Science Partners AS

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.